HEPATITIS C: THE STATE OF MEDICAID ACCESS
The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) share a commitment to ensuring that all individuals living with hepatitis C (HCV) are able to access the cure for HCV, the deadliest infectious disease in the United States.
We are pleased to report that our collaborative advocacy is working and we have seen tremendous success over the last year. Since the launch of our Hepatitis C: The State of Medicaid Access report in October 2017, 21 states have either eliminated or reduced their fibrosis restrictions, 9 have loosened their sobriety restrictions, and 6 have scaled back their prescriber restrictions.
While we have enjoyed numerous successes over the past year, our work is ongoing as states persist in imposing discriminatory treatment access restrictions. CHLPI and NVHR remain committed to capitalizing on the momentum we enjoy today and to advocating for the removal of all states’ HCV treatment access restrictions.
Eliminating treatment access restrictions is a necessary step toward ending HCV in the United States. We have the tools to eliminate HCV, but it requires the removal of all discriminatory HCV treatment access restrictions as well as leadership and resources to turn the promise of the cure into a reality for all.
For more information about Hepatitis C: The State of Medicaid Access please go to www.stateofhepc.org.